Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Indications for adjuvant endocrine treatment of breast cancer have gradually increased over the past several years. We aimed to define subgroups of patients who may or may not benefit from adjuvant endocrine therapy.
OriginalsprogEngelsk
TidsskriftNational Cancer Institute. Journal (Print)
Vol/bind103
Udgave nummer18
Sider (fra-til)1363-72
Antal sider10
ISSN0027-8874
DOI
StatusUdgivet - 2011

ID: 33154149